SURVYR

LNTH

Lantheus Holdings, Inc.
$100.15
+$0.23 (0.23%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-14%+13%+39%+66%+92%Oct 2025Oct 2026Apr 202652w high $111.8652w low $50.16
LNTHSPY
Wall St. Highest PT $115.00 (+14.8%) Wall St. Avg PT $106.99 (+6.8%)
$51$68$85$102$118POC $100Hi $115Avg $107
Underwater Drawdown %Max DD -12.8%Current -9.7%
0.0%-12.8%
Relative Strength vs SPY+58.8% vs SPYOutperforming
+94%0%-94%
1W
−$0.24 (0.24%)
1M
+$0.41 (0.41%)
3M
−$2.49 (2.43%)
6M
+$16.60 (19.87%)
YTD
+$33.60 (50.49%)
1Y
+$42.02 (72.29%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
10 analysts · mean score 2.70
1 = Strong Buy · 5 = Sell
Strong Buy110%
Buy110%
Hold880%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$100.15
Average target$106.99
+$6.84 (+6.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$102.50
Median$105.20
High$115.00
12-month Wall Street target range
Recent analyst rating changes · 30
Downgrade
2026-10-13 · Mizuho downgraded LNTH from Outperform to Neutral
Downgrade
2026-08-04 · Truist Securities downgraded LNTH from Buy to Hold
Downgrade
2026-08-04 · CJS Securities downgraded LNTH from Market Outperform to Market Perform
Downgrade
2026-08-03 · William Blair downgraded LNTH from Outperform to Market Perform
Downgrade
2026-08-03 · TD Cowen downgraded LNTH from Buy to Hold
Reiterated
2026-07-29 · Mizuho reiterated Outperform on LNTH
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.5B
P/E (last 12 months)24.2
P/E (next 12 months, estimated)15.6
52-week range$50.16 – $111.86
Revenue growth (latest quarter vs a year ago)+2.7%
Dividend yieldNo dividend
Analyst consensusHold (8)
Average analyst price target$106.99 (+7%)

What they do

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
88th percentile in sector
A-
12-1 return: +72.5%
Percentile within its GICS sector across the S&P 1500.
Growth
20th percentile in sector
D
Revenue growth (YoY): +2.7%
Percentile within its GICS sector across the S&P 1500.
Value
53rd percentile in sector
C+
Forward E/P: 6.4% · EBITDA/EV: 6.0%
Percentile within its GICS sector across the S&P 1500.
Profitability
78th percentile in sector
B+
Profit margin: +17.7% · Return on equity: +22.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

LNTH earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus$1.29 range $1.16–$1.44
Revenue consensus$358.1M 8 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026$1.55est $1.30+18.9%Above estimates
May 7, 2026$1.46est $1.23+18.8%Above estimates
Feb 26, 2026$1.67est $1.17+42.9%Above estimates
Nov 6, 2025$1.27est $1.27+0.2%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 14:24:29 ET
24-1125-0225-0525-0825-1126-0226-0526-080.001.70
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$388.2M+2.7%
2026-03-31$377.3M–
2025-12-31$406.8M–
2025-09-30$384.0M–
2025-06-30$378.0M–

News & catalysts

More news
Lantheus Holdings (LNTH) files 8-K: other event
SEC 8-K · Oct 22
Update: Market Chatter: JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal
MT Newswires · Oct 16
Market Chatter: JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal
MT Newswires · Oct 15
Rating changes
Downgrade
2026-10-13 · Mizuho downgraded LNTH from Outperform to Neutral
Downgrade
2026-08-04 · Truist Securities downgraded LNTH from Buy to Hold
Downgrade
2026-08-04 · CJS Securities downgraded LNTH from Market Outperform to Market Perform
Downgrade
2026-08-03 · William Blair downgraded LNTH from Outperform to Market Perform
Downgrade
2026-08-03 · TD Cowen downgraded LNTH from Buy to Hold
Reiterated
2026-07-29 · Mizuho reiterated Outperform on LNTH

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Lantheus Alpha Therapy, Llc
10% owner · 2026-09-04
Sell
$526.1K
Lantheus Alpha Therapy, Llc
10% owner · 2026-09-03
Sell
$250.9K
Lantheus Alpha Therapy, Llc
10% owner · 2026-09-02
Sell
$131.2K
Lantheus Holdings, Inc.
10% owner · 2026-09-01
Sell
$111.6K
Lantheus Holdings, Inc.
10% owner · 2026-08-31
Sell
$245.6K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-25 14:24:29 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026